Menu

Immune Therapy Improves Lung Cancer Patients’ Survival

Pembrolizumab combined with chemotherapy nearly doubles survival rates and shrinks tumors in some individuals.

Apr 17, 2018
Jim Daley

Micrographs of squamous carcinomaNEPHRON, WIKIMEDIA

Treating an aggressive type of lung cancer with a combination of immunotherapy and chemotherapy significantly improves patients’ survival compared with chemotherapy alone, according to a study presented yesterday (April 16) at the annual meeting of the American Association of Cancer Research (AACR). The results were also published yesterday in the New England Journal of Medicine.

“Using this combination therapy to treat patients with such an aggressive disease could be an important advance in keeping patients alive and well for longer,” says coauthor Leena Ghandi, a thoracic oncologist at NYU Langone Health, during a press conference at AACR. In an AACR statement that accompanied the press conference, Ghandi calls the results “practice-changing.”

Ghandi and her colleagues studied 616 patients with untreated metastatic non-squamous non-small cell lung cancer (NS-NSCLC) in a Phase 3 clinical trial called KEYNOTE-189: 410 patients were treated with a combination of chemotherapy and the immune checkpoint inhibitor pembrolizumab, while 206 patients received chemotherapy and a placebo. Patients in the placebo group whose disease progressed were allowed to switch into the immunotherapy group.

After 10.5 months, 69 percent of patients treated with the immunotherapy and chemotherapy combo were still alive, compared to 49 percent of patients who received chemotherapy with the placebo. In patients who received the combination treatment, 48 percent saw their tumors shrink considerably, compared with 19 percent who only received chemotherapy. On average, patients who received the combination therapy lived twice as long as patients who were not treated with it.

See “Infographic: Cancer Drug Pairings

Drugs that inhibit the cell surface receptors PD-1 and PD-L1 have been previously found to be effective therapies for targeting NS-NSCLC tumors that lack mutations in the genes EGFR and ALK. Pembrolizumab has already replaced chemotherapy as the treatment of choice in patients with tumors that express PD-L1 in more than 50 percent of cells, according to the AACR statement. However, the KEYNOTE-189 trial did not assess whether patients with high PD-L1 expression benefited from the combination therapy.

“I think most of us in the field would be quite hesitant to give up on PD-L1, or some [other] biomarker, because clearly not all patients are benefiting” from the combination therapy, Gandhi says. “We do need to focus more on how to differentiate the patients who will get the most benefit.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.